- Oral presentation
- Open Access
O09 - Early supplementation with Lactobacillus rhamnosus HN001 reduces eczema prevalence to 6 years: does it also reduce atopic sensitisation?
© Wickens et al; licensee BioMed Central Ltd. 2014
- Published: 28 February 2014
- Skin Prick Test
- High Risk Infant
- Zealand Clinical Trial Registry
- Probiotic Lactobacillus
- Cumulative Prevalence
The role of probiotics in prevention of allergic disease is still unclear; efficacy may depend on the timing, dose, duration and specific probiotic used. Using a double blind randomized placebo-controlled trial (Australian New Zealand Clinical Trials Registry: ACTRN12607000518460), we have shown that in a high risk birth cohort, maternal supplementation from 35 weeks gestation until 6 months if breastfeeding and infant supplementation from birth until 2 years with Lactobacillus rhamnosus HN001 (HN001) (6 x 109 cfu/day) halved the cumulative prevalence of eczema at 2 and 4 years. Bifidobacterium animalis subsp lactis HN019 (HN019) (9 x 109/cfu day) had no significant effect.
To determine whether differences in effects of HN001 and HN019 on eczema persist to age 6 years, and to investigate effects on sensitization.
Standard procedures were used to assess eczema (The UK Working Party’s criteria), eczema severity (SCORAD), atopic sensitization (skin prick tests (SPT), total and specific IgE) and standard questions used for asthma, wheeze and rhinoconjunctivitis.
HN001 was associated with significantly lower cumulative prevalence of eczema (HR=0.56, 95% CI 0.39-0.80), SCORAD≥10 (HR=0.69, 0.49-0.98) and SPT sensitization (HR=0.69, 95% CI 0.48-0.99). The point prevalence of eczema (RR=0.66, 95% CI 0.44-1.00), SCORAD≥10 (RR=0.62, 95% CI 0.38-1.01) and SPT sensitization (RR=0.72, 95% CI 0.53-1.00) were also reduced among children taking HN001. HN019 had no significant effect on any outcome.
This study provides evidence for the efficacy of the probiotic Lactobacillus rhamnosus HN001 in preventing the development of eczema and possibly also atopic sensitization in high risk infants to age 6 years. The absence of a similar effect for HN019 indicates that benefits may be species-specific.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.